Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald

Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald

Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports. Other equities analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Belite Bio in a report on Thursday. Benchmark restated a “buy” rating and issued a $80.00 …

Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Belite Bio (NASDAQ:BLTE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. Other research analysts also recently issued reports about the stock. Benchmark restated a “buy” rating and set a $80.00 price objective on shares of Belite Bio in […]